

EXHIBIT 53

IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF OHIO
EASTERN DIVISION

IN RE: NATIONAL PRESCRIPTION MDL No. 2804
OPIATE LITIGATION Case No. 17-md-2804

This document relates to: Judge Dan
Aaron Polster

The County of Cuyahoga v. Purdue
Pharma, L.P., et al.
Case No. 17-OP-45005
City of Cleveland, Ohio vs. Purdue
Pharma, L.P., et al.
Case No. 18-OP-45132
The County of Summit, Ohio,
et al. v. Purdue Pharma, L.P.,
et al.
Case No. 18-OP-45090

Videotaped Deposition of Joseph Rannazzisi
Washington, D.C.
April 26, 2019
8:37 a.m.

Reported by: Bonnie L. Russo
Job No. 3301876

1 a -- it was at a conference involving multiple
2 disciplines within industry and the regulated
3 -- the regulators.

4 And it came up in a conversation,
5 but I -- I don't recall exactly when.

6 BY MR. O'CONNOR:

7 Q. In your understanding, do
8 charge-backs have any role in the suspicious
9 order monitoring process?

10 MR. UTTER: Go ahead. You can
11 answer.

12 THE WITNESS: They may, yes.

13 BY MR. O'CONNOR:

14 Q. Did DEA ever issue any guidance to
15 manufacturers informing them that charge-backs
16 were to play a role in suspicious order
17 monitoring?

18 A. D --

19 MR. BENNETT: Objection. Vague.
20 And vague as to time.

21 THE WITNESS: DEA doesn't -- DEA
22 does not tell a registrant or either the man --
23 or a registrant involved in distribution
24 activities what's a suspicious order, besides
25 the -- the definition in 1301.74(b).

1 It's up to the -- the distributor or
2 the manufacturer, distributor to make a
3 decision what information they will use to
4 determine a suspicious orders.

5 BY MR. O'CONNOR:

6 Q. So DEA never issued any guidance to
7 manufacturers informing them that charge-backs
8 were to play a role in suspicious order
9 monitoring, correct?

10 MS. SINGER: Objection. Asked and
11 answered.

12 BY MR. O'CONNOR:

13 Q. I would just like a yes-or-no
14 answer.

15 MS. SINGER: Objection.

16 MR. BENNETT: Objection.

17 The witness can answer the question.

18 THE WITNESS: Besides the
19 regulations and the C.F.R. -- in the CSA, no, I
20 don't know if they ever issued a regulation --
21 any kind of document regarding chargebacks.

22 BY MR. O'CONNOR:

23 Q. Okay. When you were head of the
24 Office of Diversion Control, there was a unit
25 within that office that analyzed ARCOS data,

1 correct?

2 A. Yes.

3 Q. Did that group use ARCOS data to
4 look for leads for investigations?

5 A. They can, yes.

6 Q. Did they, in fact, do that?

7 A. Yes.

8 Q. And would you agree that analyzing
9 the ARCOS data was helpful to the agency in
10 generating leads for investigations?

11 MR. BENNETT: Objection. Vague.
12 And vague as to time.

13 THE WITNESS: The analysis of ARCOS
14 information can help, yes, leads for
15 investigations.

16 BY MR. O'CONNOR:

17 Q. Did the DEA use ARCOS for
18 investigative leads in a timely manner in your
19 view?

20 MS. SINGER: Objection. Vague.

21 MR. BENNETT: Objection. Vague.
22 And objection. Scope. Regarding opinions.

23 THE WITNESS: I don't understand
24 what you mean by "in a timely manner."

25 ARCOS is generally three to six